deltatrials
Completed PHASE2 NCT00173862

Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC

A Phase II Study of Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced Transitional Cell Carcinoma

Sponsor: National Taiwan University Hospital

Conditions Transitional Cell Carcinoma
Interventions Gemcitabine, Ifosfamide
Updated 5 times since 2017 Last updated: Jul 23, 2007 Started: May 31, 2000 Completion: Jun 30, 2006

This PHASE2 trial investigates Transitional Cell Carcinoma and is currently completed. National Taiwan University Hospital leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

May 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Taiwan University Hospital
Data source: National Taiwan University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Taipei, Taiwan